Abstract Body

Background: Injectable hormonal contraception (HC) use has been associated with increased risk of HIV acquisition in women, but findings are inconsistent. The pathophysiology of how injectable HC use might increase HIV risk is unclear. Heightened risk for other sexually transmitted infections (STI) has been postulated as a possible mechanism, but it is unknown if injectable HC increases risk for other viral STIs. We assessed the association between oral and injectable HC use and incident herpes simplex virus type 2 (HSV-2), which is a risk factor for HIV acquisition.

Methods: Risk of incident HSV-2 associated with HC use was assessed among 682 HIV and HSV-2-negative women whose HIV-negative male partners were enrolled in a trial of medical male circumcision in Rakai, Uganda. Women were followed annually over two years. HSV-2 incidence was compared among women using injectable HC stratified into consistent, newly initiated, or discontinued use between visits, women using oral HC, pregnant women, and women who were neither pregnant nor using HC (referent group). Hazard ratios (HR) were estimated using discrete-time Cox proportional hazards models with adjustment for demographics, sexual behaviors, and condom use.

Results: We identified 70 incident HSV-2 events. Incidence was 13.1/100 person-years (py) among women consistently using injectable HC, and 3.9 and 5.2/100 py among women initiating and discontinuing injectable HC, respectively. Incidence was 2.8/100 py among oral HC users, while among non-HC users, incidence was 4.3/100 py in pregnant women and 6.6/100 py in non-pregnant non-HC using women. Compared to women who were neither pregnant nor using HC, the adjusted hazard ratio of HSV-2 acquisition among women consistently using injectable HC was 2.26 (95%CI: 1.09-4.69, p=0.029). Among 132 women with HSV-2 positive partners, incidence was 36.4/100 py in consistent injectable HC users and 10.6/100 py in women who were neither pregnant nor using HC (adjHR: 6.23; 1.49-26.3, p=0.012). There was no increased risk for HSV-2 among women who recently initiated or discontinued injectable HC, oral HC users, or pregnant women.

Conclusions: Our data suggest consistent use of injectable HC is associated with increased risk of HSV-2 acquisition. The findings may be relevant to the associations between HIV risk and use of injectable HC in some prior studies, and might indicate that injectable methods broadly affect the risk of viral sexually transmitted infections in women.